Trexquant Investment LP Makes New $304,000 Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Trexquant Investment LP purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYNFree Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 22,822 shares of the company’s stock, valued at approximately $304,000.

Several other large investors also recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Dyne Therapeutics by 5.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,921 shares of the company’s stock worth $305,000 after buying an additional 1,199 shares during the period. Principal Financial Group Inc. boosted its position in shares of Dyne Therapeutics by 10.7% during the third quarter. Principal Financial Group Inc. now owns 15,229 shares of the company’s stock worth $136,000 after buying an additional 1,476 shares during the period. Profund Advisors LLC boosted its position in shares of Dyne Therapeutics by 9.8% during the third quarter. Profund Advisors LLC now owns 23,793 shares of the company’s stock worth $213,000 after buying an additional 2,131 shares during the period. New York State Common Retirement Fund boosted its position in shares of Dyne Therapeutics by 13.7% during the fourth quarter. New York State Common Retirement Fund now owns 18,592 shares of the company’s stock worth $247,000 after buying an additional 2,244 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of Dyne Therapeutics by 4.9% during the third quarter. Wellington Management Group LLP now owns 115,935 shares of the company’s stock worth $1,039,000 after buying an additional 5,371 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Insider Transactions at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 2,672 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $25.28, for a total transaction of $67,548.16. Following the transaction, the senior vice president now owns 119,283 shares in the company, valued at $3,015,474.24. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, SVP Richard William Scalzo sold 2,672 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $25.28, for a total transaction of $67,548.16. Following the transaction, the senior vice president now owns 119,283 shares in the company, valued at $3,015,474.24. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Joshua T. Brumm sold 66,387 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $25.67, for a total value of $1,704,154.29. Following the transaction, the chief executive officer now owns 537,998 shares in the company, valued at approximately $13,810,408.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 126,716 shares of company stock worth $3,497,318. Company insiders own 20.77% of the company’s stock.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $31.41 on Wednesday. The stock’s 50 day moving average price is $27.64 and its two-hundred day moving average price is $21.88. The firm has a market capitalization of $2.74 billion, a price-to-earnings ratio of -7.91 and a beta of 1.06. Dyne Therapeutics, Inc. has a 12-month low of $6.40 and a 12-month high of $35.98.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.81). Equities research analysts expect that Dyne Therapeutics, Inc. will post -3.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on DYN shares. Stifel Nicolaus upped their price objective on Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. HC Wainwright increased their price target on Dyne Therapeutics from $36.00 to $48.00 and gave the company a “buy” rating in a research report on Monday, May 20th. Jefferies Financial Group increased their price target on Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, May 20th. Oppenheimer reissued an “outperform” rating and set a $47.00 price target on shares of Dyne Therapeutics in a research report on Monday, May 6th. Finally, Piper Sandler increased their price target on Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $40.78.

Read Our Latest Report on Dyne Therapeutics

About Dyne Therapeutics

(Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Read More

Institutional Ownership by Quarter for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.